Overview

IGF-1 LR3 (Long R3 IGF-1) is a synthetic 83-amino acid analog of human IGF-1, engineered with two modifications: a 13-amino acid N-terminal extension and a glutamic acid to arginine substitution at position 3. These changes reduce IGF Binding Protein (IGFBP) affinity by approximately 1000-fold compared to native IGF-1, while maintaining full IGF-1 receptor (IGF-1R) binding. The result is dramatically prolonged in vivo activity as the peptide cannot be sequestered by circulating IGFBPs, extending its anabolic window from hours to over 24 hours.

Mechanism of Action

IGF-1 LR3 binds IGF-1R on target cells (muscle, bone, liver) and activates the PI3K/Akt/mTORC1 signaling cascade, driving protein synthesis, cell proliferation, and anti-apoptotic signaling. In myoblasts, it sustains pAkt(Ser473) elevation 2.2-2.8× above baseline for 48-56 hours versus 24-30 hours for native IGF-1. mTORC1 activity remains elevated at 48 hours (1.8-2.4×), supporting sustained translational upregulation. It also suppresses MuRF-1 and MAFbx/Atrogin-1 atrophy E3 ligases by 34-42% via Akt-dependent FoxO1/FoxO3a nuclear exclusion.

Potential Benefits

  • Sustained anabolic signaling lasting >24 hours per dose
  • Significant lean muscle mass gains
  • Anti-atrophy protection in denervation, immobilization, and cachexia models
  • Improved muscle recovery from injury
  • Enhanced satellite cell maintenance (28-34% more Pax7+ cells)
  • Increased grip strength and functional performance in animal models
  • Enhanced VEGF signaling increasing capillary density in muscle

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range40-120 mcg/day
Beginner40-50 mcg/day post-workout
Intermediate80-100 mcg/day (single or split dose)
Advanced100-150 mcg/day (experienced users with medical monitoring)
Cycle Duration4-6 weeks maximum
Cycle Off4-6 weeks minimum between cycles

Extended half-life (20-30 hours vs 15 min for native IGF-1) allows once-daily dosing. Best dosed immediately post-workout. Hypoglycemia risk — always have fast-acting carbohydrates available. Mandatory cycle breaks for IGF-1 receptor sensitivity recovery.

Routes of Administration

Subcutaneous Injection High

Standard research route; local fat injection may increase local muscle uptake

Intramuscular Injection High

Direct muscle injection post-workout; potentially better local IGF-1R activation in target muscle

Stacking Protocols

Popular research stacks involving IGF-1 LR3:

Muscle Growth Stack

Multi-point anabolic axis activation for maximum muscle growth

IGF-1 LR3 acts downstream of GH; MK-677 and CJC-1295 elevate endogenous GH and IGF-1 upstream; covers the full GH/IGF-1 axis.

Performance + Recovery Stack

Anabolic environment with accelerated tissue repair for athletes

IGF-1 LR3 drives anabolic signaling; BPC-157 and TB-500 prevent and repair training-related injuries.

Reconstitution

Typical Vial Size1mg, 2mg
BAC Water1-2ml per 1mg vial; use 0.6% acetic acid if recommended for stability
StorageRefrigerate at 2-8°C after reconstitution; highly sensitive to temperature
Shelf Life14-21 days refrigerated; acetic acid diluent may extend to 28 days

Need exact syringe measurements?

Amino Acid Sequence

13-aa N-terminal extension + modified IGF-1 sequence with Arg at position 3 (83 total amino acids)

Side Effects & Safety

  • Hypoglycemia (potent glucose uptake effect)
  • Potential tumor growth promotion (IGF-1R is a mitogenic receptor)
  • Acromegaly-like symptoms at high doses
  • Joint pain and fluid retention
  • Theoretical cancer risk with long-term use

Synergistic Compounds

The following compounds have been studied alongside IGF-1 LR3 for potential complementary or synergistic effects:

MGF (sequential use: MGF first, then IGF-1 LR3)Follistatin-344BPC-157

Learn More

References & Further Reading

  • [object Object]
  • [object Object]